Study Design of the Diacerein in Patients With Covid-19
Status:
Not yet recruiting
Trial end date:
2022-07-08
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind trial pilot study. This study will
include individuals over 18 years of age who have been hospitalized with a confirmed
diagnosis of COVID-19 to assess whether DIACEREIN treatment is safe and effective in
controlling or decreasing inflammation in the body and viral load (amount of virus in the
body in these patients).
Phase:
Phase 2
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo